Full-Time

Director – Medical Science Liaison

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$220k - $260kAnnually

+ Commission + Bonus

Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Marketing
Requirements
  • Doctoral degree in scientific or medical discipline.
  • 8+ years’ experience as an MSL or in a similar role within the pharmaceutical or biotech industry.
  • Strong understanding of clinical research methodologies and drug development processes.
  • Knowledge and experience within the oncology therapeutic area.
  • Excellent verbal and written communication skills.
  • Proven ability to analyze and synthesize scientific information effectively.
  • Excellent presentation skills, with the ability to effectively communicate complex scientific data to diverse audiences.
  • Strong networking skills with proven ability to successfully build and maintain relationships with KOLs and healthcare professionals.
  • Self-directed and able to thrive in a fast-paced and dynamic environment.
  • Willingness to travel up to 60% of time.
Responsibilities
  • Develop and maintain strong relationships with KOLs, healthcare professionals, and academic institutions to advance scientific and medical knowledge.
  • Communicate clinical and scientific data to KOLs and healthcare professionals through presentations, educational programs, and scientific discussions.
  • Support the synthesis and communicate scientific insights from KOLs to relevant internal teams.
  • Provide scientific support for medical congresses, advisory boards and other relevant scientific engagements to enhance the visibility of RevMed within the scientific and medical communities.
  • Establish credibility as a scientific expert and resource for internal stakeholders, providing medical and scientific support for products and therapeutic areas.
  • Collaborate cross-functionally with medical affairs, clinical development, marketing and other teams to support the development and execution of medical strategies and tactics.
  • Stay current with scientific literature, emerging research, and competitive landscape.
  • Adhere to Revolution Medicines Core Values and policies.
  • Understand the regulatory requirements for customer engagement by field-based employees.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, which target and inhibit the RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to tailor their research and development efforts to this specific area. Their goal is to improve cancer treatment outcomes for patients with RAS mutations by providing effective targeted therapies.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Strong investor confidence shown by recent upsized public offering and stock options.
  • Growing interest in targeted cancer therapies boosts investment and partnership opportunities.

What critics are saying

  • EQRx acquisition may lead to integration challenges and cultural clashes.
  • $600M public stock offering could result in shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?